Compare ICMB & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICMB | NRSN |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 14.2M |
| IPO Year | 2013 | 2021 |
| Metric | ICMB | NRSN |
|---|---|---|
| Price | $0.87 | $6.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 29.8K | ★ 515.9K |
| Earning Date | 05-13-2026 | 03-31-2026 |
| Dividend Yield | ★ 21.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.43 | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.25 |
| 52 Week High | $3.12 | $1.30 |
| Indicator | ICMB | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 96.50 |
| Support Level | $0.86 | $0.66 |
| Resistance Level | $0.89 | N/A |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.01 | 0.41 |
| Stochastic Oscillator | 65.79 | 100.00 |
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). The investment objective of the company is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.